Analyzing AmerisourceBergen (ABC) and biOasis Technologies (BIOAF)

AmerisourceBergen (NYSE:ABC) and biOasis Technologies (OTCMKTS:BIOAF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Valuation & Earnings

This table compares AmerisourceBergen and biOasis Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AmerisourceBergen $167.94 billion 0.11 $1.66 billion $6.49 13.70
biOasis Technologies $460,000.00 34.26 -$4.12 million N/A N/A

AmerisourceBergen has higher revenue and earnings than biOasis Technologies.

Volatility and Risk

AmerisourceBergen has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, biOasis Technologies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for AmerisourceBergen and biOasis Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AmerisourceBergen 0 6 9 0 2.60
biOasis Technologies 0 0 0 0 N/A

AmerisourceBergen presently has a consensus price target of $100.71, indicating a potential upside of 13.28%. Given AmerisourceBergen’s higher probable upside, equities research analysts plainly believe AmerisourceBergen is more favorable than biOasis Technologies.

Profitability

This table compares AmerisourceBergen and biOasis Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AmerisourceBergen 0.99% 45.54% 3.80%
biOasis Technologies -1,517.77% -407.59% -264.48%

Dividends

AmerisourceBergen pays an annual dividend of $1.60 per share and has a dividend yield of 1.8%. biOasis Technologies does not pay a dividend. AmerisourceBergen pays out 24.7% of its earnings in the form of a dividend. AmerisourceBergen has raised its dividend for 13 consecutive years.

Institutional and Insider Ownership

64.7% of AmerisourceBergen shares are owned by institutional investors. 27.3% of AmerisourceBergen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AmerisourceBergen beats biOasis Technologies on 12 of the 14 factors compared between the two stocks.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company's Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

biOasis Technologies Company Profile

biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in Vancouver, Canada.

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit